Ostrowitzki, Susanne, Deptula, Dennis, Thurfjell, Lennart, Barkhof, Frederik, Bohrmann, Bernd, Brooks, David J., Klunk, William E., Ashford, Elizabeth, Yoo, Kisook, Xu, Zhi-Xin, Loetscher, Hansruedi, Santarelli, Luca

Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]

Kasuya, Masashi, Meguro, Kenichi, Okamura, Nobuyuki, Funaki, Yoshihito, Ishikawa, Hiroyasu, Tanaka, Naofumi, Iwata, Ren, Yanai, Kazuhiko

The aim of the study was to predict donepezil responders among patients with Alzheimer disease (AD) based on cognitive tests and positron emission tomography. The Mini-Mental State Examination, Digit Symbol subtest (DigSm) of Wechsler Adult Intelligence Scale Revised, and Trail-Making Test A were administered for 80 patients with AD to assess global function, attention, and […]

Egefjord, Lærke, Gejl, Michael, Møller, Arne, Brændgaard, Hans, Gottrup, Hanne, Antropova, Olga, Møller, Niels, Poulsen, Henrik E., Gjedde, Albert, Brock, Birgitte, Rungby, Jørgen

Introduction: Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated […]

Bahar-Fuchs, Alex, Villemagne, Victor, Ong, Kevin, Chetélat, Gaël, Lamb, Fiona, Reininger, Cornelia B., Woodward, Michael, Rowe, Christopher C.

Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted mainly to research settings. The identification of […]